CN112957379B - Method for extracting centella asiatica extract - Google Patents
Method for extracting centella asiatica extract Download PDFInfo
- Publication number
- CN112957379B CN112957379B CN202110193793.3A CN202110193793A CN112957379B CN 112957379 B CN112957379 B CN 112957379B CN 202110193793 A CN202110193793 A CN 202110193793A CN 112957379 B CN112957379 B CN 112957379B
- Authority
- CN
- China
- Prior art keywords
- centella asiatica
- cyclodextrin
- extracting
- asiatica extract
- centella
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims abstract description 26
- 229940059958 centella asiatica extract Drugs 0.000 title claims description 29
- 229920000858 Cyclodextrin Polymers 0.000 claims abstract description 43
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims abstract description 42
- QCYLIQBVLZBPNK-UHFFFAOYSA-N asiaticoside A Natural products O1C(C(=O)C(C)C)=CC(C)C(C2(C(OC(C)=O)CC34C5)C)C1CC2(C)C3CCC(C1(C)C)C45CCC1OC1OCC(O)C(O)C1O QCYLIQBVLZBPNK-UHFFFAOYSA-N 0.000 claims abstract description 39
- BNMGUJRJUUDLHW-HCZMHFOYSA-N Madecassoside Chemical compound O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O)OC[C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)OC(=O)[C@]12CC[C@H]([C@@H]([C@H]1C=1[C@@]([C@@]3(C[C@@H](O)[C@H]4[C@](C)(CO)[C@@H](O)[C@H](O)C[C@]4(C)[C@H]3CC=1)C)(C)CC2)C)C)[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O BNMGUJRJUUDLHW-HCZMHFOYSA-N 0.000 claims abstract description 29
- BNMGUJRJUUDLHW-HLUHVYOBSA-N Madecassoside Natural products C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5[C@H](O)C[C@@]34C)[C@@H]2[C@H]1C)C(=O)O[C@@H]6O[C@H](CO[C@@H]7O[C@H](CO)[C@@H](O[C@@H]8O[C@H](C)[C@H](O)[C@@H](O)[C@H]8O)[C@H](O)[C@H]7O)[C@@H](O)[C@H](O)[C@H]6O BNMGUJRJUUDLHW-HLUHVYOBSA-N 0.000 claims abstract description 29
- 239000000284 extract Substances 0.000 claims abstract description 29
- 229940090813 madecassoside Drugs 0.000 claims abstract description 29
- 238000000605 extraction Methods 0.000 claims abstract description 16
- NNWMHSNRRWMMBI-PJISEHJASA-N Asiaticoside B Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](OC[C@@H]2[C@H]([C@H](O)[C@@H](O)[C@H](OC(=O)[C@@]34[C@@H](CC(C)(C)CC3)C=3[C@@]([C@]5(C)C[C@@H](O)[C@H]6[C@](C)(CO)[C@@H](O)[C@H](O)C[C@]6(C)[C@H]5CC=3)(C)CC4)O2)O)[C@H](O)[C@H]1O NNWMHSNRRWMMBI-PJISEHJASA-N 0.000 claims abstract description 12
- 241000167550 Centella Species 0.000 claims abstract description 10
- 229940022757 asiaticoside Drugs 0.000 claims abstract description 10
- WYQVAPGDARQUBT-XCWYDTOWSA-N asiaticoside Natural products O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@H](O)[C@H](O[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)[C@@H](CO)O2)O1)[C@@]12[C@@H]([C@@H](C)[C@H](C)CC1)C=1[C@](C)([C@@]3(C)[C@@H]([C@@]4(C)[C@H]([C@@](CO)(C)[C@@H](O)[C@H](O)C4)CC3)CC=1)CC2 WYQVAPGDARQUBT-XCWYDTOWSA-N 0.000 claims abstract description 10
- WYQVAPGDARQUBT-FGWHUCSPSA-N Madecassol Chemical compound O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O)OC[C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)OC(=O)[C@]12CC[C@H]([C@@H]([C@H]1C=1[C@@]([C@@]3(CC[C@H]4[C@](C)(CO)[C@@H](O)[C@H](O)C[C@]4(C)[C@H]3CC=1)C)(C)CC2)C)C)[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O WYQVAPGDARQUBT-FGWHUCSPSA-N 0.000 claims abstract description 9
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 claims description 48
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims description 46
- 244000146462 Centella asiatica Species 0.000 claims description 42
- 235000004032 Centella asiatica Nutrition 0.000 claims description 42
- 238000001914 filtration Methods 0.000 claims description 36
- 239000012528 membrane Substances 0.000 claims description 30
- 239000000706 filtrate Substances 0.000 claims description 28
- 238000002156 mixing Methods 0.000 claims description 28
- 239000000243 solution Substances 0.000 claims description 28
- 238000003756 stirring Methods 0.000 claims description 27
- 239000007864 aqueous solution Substances 0.000 claims description 25
- -1 polypropylene Polymers 0.000 claims description 25
- 239000000843 powder Substances 0.000 claims description 24
- 239000004743 Polypropylene Substances 0.000 claims description 23
- 229920001155 polypropylene Polymers 0.000 claims description 23
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 20
- 239000007787 solid Substances 0.000 claims description 18
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 16
- 239000004626 polylactic acid Substances 0.000 claims description 16
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 claims description 14
- 238000000108 ultra-filtration Methods 0.000 claims description 14
- 239000004698 Polyethylene Substances 0.000 claims description 10
- 229920000573 polyethylene Polymers 0.000 claims description 10
- 238000002390 rotary evaporation Methods 0.000 claims description 10
- 239000003960 organic solvent Substances 0.000 claims description 9
- 239000002904 solvent Substances 0.000 claims description 9
- 239000012466 permeate Substances 0.000 claims description 7
- 238000007873 sieving Methods 0.000 claims description 7
- 238000009210 therapy by ultrasound Methods 0.000 claims description 7
- 229920001427 mPEG Polymers 0.000 claims description 6
- 238000010298 pulverizing process Methods 0.000 claims description 5
- 238000002791 soaking Methods 0.000 claims description 5
- 238000009835 boiling Methods 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims 1
- 238000000746 purification Methods 0.000 abstract description 2
- 239000013543 active substance Substances 0.000 abstract 1
- 238000005238 degreasing Methods 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 45
- 210000004379 membrane Anatomy 0.000 description 20
- 230000000052 comparative effect Effects 0.000 description 16
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 238000010438 heat treatment Methods 0.000 description 10
- 230000007794 irritation Effects 0.000 description 9
- 238000005303 weighing Methods 0.000 description 8
- 241000196324 Embryophyta Species 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 5
- 238000001704 evaporation Methods 0.000 description 5
- 239000011148 porous material Substances 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 4
- 238000004440 column chromatography Methods 0.000 description 4
- 239000008367 deionised water Substances 0.000 description 4
- 229910021641 deionized water Inorganic materials 0.000 description 4
- 238000004821 distillation Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000004042 decolorization Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 208000037319 Hepatitis infectious Diseases 0.000 description 2
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 2
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- JXSVIVRDWWRQRT-UYDOISQJSA-N asiatic acid Chemical compound C1[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C JXSVIVRDWWRQRT-UYDOISQJSA-N 0.000 description 2
- 229940011658 asiatic acid Drugs 0.000 description 2
- LBGFKBYMNRAMFC-PYSQTNCISA-N asiatic acid Natural products C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5CC[C@@]34C)[C@]2(C)[C@H]1C)C(=O)O LBGFKBYMNRAMFC-PYSQTNCISA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- CLXOLTFMHAXJST-UHFFFAOYSA-N esculentic acid Natural products C12CC=C3C4CC(C)(C(O)=O)CCC4(C(O)=O)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(CO)C CLXOLTFMHAXJST-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- 150000002338 glycosides Chemical class 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 208000005252 hepatitis A Diseases 0.000 description 2
- BJQWYEJQWHSSCJ-UHFFFAOYSA-N heptacosane Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCC BJQWYEJQWHSSCJ-UHFFFAOYSA-N 0.000 description 2
- IYRMWMYZSQPJKC-UHFFFAOYSA-N kaempferol Chemical compound C1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 IYRMWMYZSQPJKC-UHFFFAOYSA-N 0.000 description 2
- PRAUVHZJPXOEIF-AOLYGAPISA-N madecassic acid Chemical compound C1[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]2[C@H](O)C[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C PRAUVHZJPXOEIF-AOLYGAPISA-N 0.000 description 2
- 229940011656 madecassic acid Drugs 0.000 description 2
- BUWCHLVSSFQLPN-UHFFFAOYSA-N madecassic acid Natural products CC1CCC2(CCC3(C)C(=CCC4C5(C)CC(O)C(O)C(C)(C5CCC34C)C(=O)O)C2C1C)C(=O)OC6OC(COC7OC(CO)C(OC8OC(C)C(O)C(O)C8O)C(O)C7O)C(O)C(O)C6O BUWCHLVSSFQLPN-UHFFFAOYSA-N 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 235000005875 quercetin Nutrition 0.000 description 2
- 229960001285 quercetin Drugs 0.000 description 2
- 229930182493 triterpene saponin Natural products 0.000 description 2
- GUFMBISUSZUUCB-UHFFFAOYSA-N 1,3,5-tritert-butylbenzene Chemical compound CC(C)(C)C1=CC(C(C)(C)C)=CC(C(C)(C)C)=C1 GUFMBISUSZUUCB-UHFFFAOYSA-N 0.000 description 1
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- DEXFNLNNUZKHNO-UHFFFAOYSA-N 6-[3-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperidin-1-yl]-3-oxopropyl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1CCN(CC1)C(CCC1=CC2=C(NC(O2)=O)C=C1)=O DEXFNLNNUZKHNO-UHFFFAOYSA-N 0.000 description 1
- 206010059245 Angiopathy Diseases 0.000 description 1
- 241000208173 Apiaceae Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- WCWVHRLNPFPNHF-UHFFFAOYSA-N CCCCCCCCCCCCCCCCCCCCCCCCCCOC(=O)CCCCCCC Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCOC(=O)CCCCCCC WCWVHRLNPFPNHF-UHFFFAOYSA-N 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- UBSCDKPKWHYZNX-UHFFFAOYSA-N Demethoxycapillarisin Natural products C1=CC(O)=CC=C1OC1=CC(=O)C2=C(O)C=C(O)C=C2O1 UBSCDKPKWHYZNX-UHFFFAOYSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 244000085625 Equisetum Species 0.000 description 1
- 206010015946 Eye irritation Diseases 0.000 description 1
- 206010018366 Glomerulonephritis acute Diseases 0.000 description 1
- 108010078851 HIV Reverse Transcriptase Proteins 0.000 description 1
- 206010019345 Heat stroke Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000209046 Pennisetum Species 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 206010048038 Wound infection Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 231100000851 acute glomerulonephritis Toxicity 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 238000004061 bleaching Methods 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 210000003837 chick embryo Anatomy 0.000 description 1
- 210000003711 chorioallantoic membrane Anatomy 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 231100000013 eye irritation Toxicity 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 235000008777 kaempferol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- YQUVCSBJEUQKSH-UHFFFAOYSA-N protochatechuic acid Natural products OC(=O)C1=CC=C(O)C(O)=C1 YQUVCSBJEUQKSH-UHFFFAOYSA-N 0.000 description 1
- 235000019633 pungent taste Nutrition 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000011076 safety test Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- WKOLLVMJNQIZCI-UHFFFAOYSA-N vanillic acid Chemical compound COC1=CC(C(O)=O)=CC=C1O WKOLLVMJNQIZCI-UHFFFAOYSA-N 0.000 description 1
- TUUBOHWZSQXCSW-UHFFFAOYSA-N vanillic acid Natural products COC1=CC(O)=CC(C(O)=O)=C1 TUUBOHWZSQXCSW-UHFFFAOYSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
- C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/15—Preparation or pretreatment of starting material involving mechanical treatment, e.g. chopping up, cutting or grinding
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Alternative & Traditional Medicine (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Botany (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Steroid Compounds (AREA)
Abstract
The invention belongs to the technical field of natural active substance extraction, and particularly relates to an extraction method of a centella extract. The method comprises the process steps of degreasing, decoloring, cyclodextrin inclusion, asiaticoside and asiaticoside B removal, madecassoside purification and the like.
Description
Technical Field
The invention belongs to the technical field of extraction of bioactive substances, and particularly relates to an extraction method of a centella extract.
Background
Centella asiatica (L.) Urban is a whole plant of Centella asiatica of the family umbelliferae, a perennial creeping herb, which is mainly distributed in the south of the Yangtze river valley, also known as big bowl, herba patriniae, equisetum vulgare, herba solidaginis, pennisetum semiliquidum and the like, and is a common traditional Chinese medicine collected by the Chinese pharmacopoeia. The Shennong Ben Cao Jing records its cold nature, bitter and pungent taste; has effects of clearing heat, promoting diuresis, removing toxic substances, relieving swelling, promoting blood circulation, removing blood stasis, and promoting urination. It is clinically used in surgery, dermatology, infectious hepatitis, epidemic cerebrospinal meningitis, carbuncle, sore, diarrhea due to heatstroke, stranguria with bloody stranguria, jaundice due to damp-heat, etc.
The centella asiatica extract has various pharmacological activities of resisting bacteria, oxidation and tumors, resisting HIV reverse transcriptase activity, regulating immunity, resisting depression and the like. Can be used for treating skin surgical diseases such as intractable wound and skin tuberculosis. It is also used for treating forceps angiopathy, infectious hepatitis, acute glomerulonephritis, epidemic cerebral vertebritis, skin wound, and epidemic parotitis.
The centella asiatica extract mainly comprises the following effective components: asiaticoside (Asiatotal glycosides), Madecassoside (Madecassoside) and Asiaticoside-B (Asiatotal glycosides B), which belong to triterpene saponins and are collectively called Asiaticoside (Chinese pharmacopoeia 2010 edition); the centella also comprises the following chemical components: asiatic acid, madecassic acid, asiaticoside, n-heptacosane, 2,4, 6-tri-tert-butylbenzene, p-hydroxybenzoic acid, tagetetin, quercetin, hexacosanol caprylate, kaempferol, quercetin, carotene, vanillic acid, succinic acid, terminoli cacid, and the like. The structures of these components are complex and similar, and there are only slight differences in the positions or amounts in the composition of hydroxyl groups, methyl groups, and double bonds. They often have sugar chains with the same structure while having slight structural differences, and under the influence of the sugar chains, the differences become even smaller, and even contain multiple pairs of isomers, so that the separation and purification work of the centella asiatica extract is quite difficult.
Asiaticoside and madecassoside are active ingredients with higher content in centella asiatica, and have the effects of reducing inflammatory cell infiltration, promoting dermal fiber cell proliferation to form epithelium, stimulating cell growth, promoting wound healing, preventing wound infection and the like. Madecassoside has better water solubility than madecassoside due to its effects of healing wound and whitening skin, and is widely used in the cosmetic industry.
The prior art is mostly characterized in that the method for extracting high-purity madecassoside from centella asiatica comprehensively utilizes the steps of activated carbon decolorization, repeated column chromatography, recrystallization and the like. However, decolorization and repeated crystallization of activated carbon can result in large loss and low yield of madecassoside; the repeated column chromatography not only has complex process, but also needs to consume a large amount of time and organic solvent, thus being not beneficial to the reduction of production cost and environmental protection.
Cyclodextrins have a hollow cavity structure and can be combined with various compounds to form host-guest inclusion compounds, thereby increasing the solubility of the compounds. In recent years, studies on extraction of active ingredients of traditional Chinese medicines using cyclodextrin have been increasing. Researches show that the cyclodextrin can improve the extraction rate of insoluble components. However, the prior art for selectively extracting madecassoside by using cyclodextrin is not seen at present.
Disclosure of Invention
In order to solve the problems, the invention provides a method for preparing madecassoside without decoloring by active carbon, repeated column chromatography and recrystallization. The method is green and environment-friendly, and the biological safety of the obtained product is higher.
In order to achieve the technical effects, the technical scheme adopted by the invention comprises the following steps:
(1) pulverizing and sieving the whole centella asiatica, soaking the centella asiatica in an organic solvent to remove fat-soluble substances, and then removing the solvent to collect the centella asiatica powder;
(2) stirring and extracting the centella powder obtained in the step (1) for multiple times by using an aqueous solution containing hydrogen peroxide and cyclodextrin, wherein the weight ratio of the aqueous solution containing hydrogen peroxide and cyclodextrin to the centella powder is 10: 1-15: 1. mixing the extractive solutions, adding appropriate amount of cyclodextrin, and stirring to obtain herba Centellae extractive solution;
(3) sequentially filtering the centella asiatica extract obtained in the step (2) by using 0.5-micrometer and 0.22-micrometer polypropylene membranes, then adding methoxy-polyethylene glycol-polylactic acid (mPEG-PLA), performing negative pressure rotary evaporation, concentrating to 1/3-1/4 of the original volume, filtering by using a 50-nm ultrafiltration membrane, collecting ultrafiltration permeate, and concentrating to obtain an extract to obtain a centella asiatica extract;
(4) mixing the centella asiatica extract obtained in the step (3) with high-concentration ethanol, stirring, filtering by using a 0.5-micron polypropylene membrane, discarding the filtrate, and collecting the solid;
(5) mixing the solid obtained in the step (4) with a low-boiling-point organic solvent, carrying out high-frequency high-power ultrasonic treatment, filtering by using a 0.22-micrometer polypropylene membrane, and collecting filtrate; repeating the above steps; mixing the filtrates, removing organic solvent by rotary evaporation, and drying to obtain herba Centellae extract with high biological safety.
Preferably, in the aqueous solution containing hydrogen peroxide and cyclodextrin in the step (2), the concentration of hydrogen peroxide is 10-15%, and the concentration of cyclodextrin is 2-5%.
Preferably, the cyclodextrin in step (2) is 2-hydroxypropyl- β -cyclodextrin, and the molecular formula is: c42H63O35(C3H7O)7(ii) a Molecular weight: 1542.
preferably, a proper amount of cyclodextrin is added in the step (2), and the addition amount of the cyclodextrin is 1-2% of the total weight of the aqueous solution containing hydrogen peroxide and cyclodextrin.
Preferably, the methoxy-polyethylene glycol-polylactic acid in the step (3) has a molecular weight of 750g/mol in the mPEG section and a molecular weight of 4000g/mol in the PLA section, and the addition weight is 20-30% of the weight of the centella asiatica powder in the step (1).
Preferably, the weight ratio of the high-concentration ethanol to the centella asiatica extract in the step (4) is not more than 8: 1; and the high concentration ethanol has a water content of less than 5%.
Preferably, the ultrasonic frequency adopted by the high-frequency high-power ultrasonic treatment in the step (5) is 10-20 KHz, and the power intensity is 200-300W per square meter.
Preferably, the low-boiling organic solvent in step (5) is 2-butanol.
Preferably, the weight ratio of the total amount of the lower boiling organic solvent used to the solids in step (5) is 5: 1.
The high-purity madecassoside obtained by the technical scheme is white to off-white powder, the water solubility is very good, and HPLC analysis shows that the content of the madecassoside is higher, the contents of the asiaticoside and the asiaticoside B are lower, and the madecassoside are not contained.
The technical scheme provided by the invention has the following beneficial effects:
1) the triterpene saponin component in centella asiatica is coated by 2-hydroxypropyl-beta-cyclodextrin with molecular weight of 1542, pigment is not easy to coat, and other components are less coated. And the hydroxyl asiaticoside obtained finally has high purity and light color by the bleaching action of hydrogen peroxide and the synergy of the two. Avoids the loss of madecassoside caused by adopting activated carbon for decolorization, column chromatography and recrystallization, and has high yield.
2) Methoxy-polyethylene glycol-polylactic acid with 750g/mol of mPEG section molecular weight and 4000g/mol of PLA section molecular weight is selected to remove asiaticoside and asiaticoside B.
3) The cyclodextrin inclusion is treated by high-frequency high-power ultrasonic waves, and the released active ingredient is mainly madecassoside.
The extraction method provided by the invention has the advantages of simple and environment-friendly process, high product yield, light color, high biological safety and wide application range.
Detailed Description
The technical solution of the present invention will be described in further detail with reference to specific embodiments. It should be noted that variations and modifications can be made by persons skilled in the art without departing from the spirit of the invention. All falling within the scope of the present invention.
Example 1, high purity madecassoside was extracted.
(1) Taking the whole grass of centella asiatica (the producing area is Yibin city, Sichuan province, the same below), pulverizing, and sieving with a 10-mesh sieve. Removing powder with too large particle size and unable to pass through sieve mesh, weighing 100 g of sieved herba Centellae powder, placing in 2L round bottom flask, adding 1 kg of ethyl acetate, soaking at 40 deg.C for 1.5 hr, and filtering to remove ethyl acetate.
(2) The cyclodextrin adopted in the embodiment is 2-hydroxypropyl-beta-cyclodextrin, and the molecular weight is 1541.54; the molecular formula is C42H63O35(C3H7O)7. Accurately weighing a proper amount of cyclodextrin and hydrogen peroxide, and dissolving the cyclodextrin and the hydrogen peroxide in water to obtain an aqueous solution with the weight percentage of 10% of hydrogen peroxide and the weight percentage of 2% of cyclodextrin. And (2) fully mixing the centella asiatica powder treated by the ethyl acetate in the step (1) with 1000 ml of aqueous solution containing hydrogen peroxide and cyclodextrin. Heating in water bath at a temperature not higher than 75 deg.C, stirring at 120 rpm, and extracting for 1 hr; filtering to obtain extractive solution, adding 1000 ml of aqueous solution containing hydrogen peroxide and cyclodextrin into the residue, extracting again, and filtering to obtain extractive solution. Mixing the two extractive solutions, adding 20 g of cyclodextrin into the solution, stirring at 50 deg.C for 3 hr at a stirring speed of 80 rpm to obtain herba Centellae extractive solution.
(3) Filtering the centella asiatica extract obtained in the step (2) by using 0.5 mu m and 0.22 mu m polypropylene membranes in sequence, then adding 20 g of methoxy-polyethylene glycol-polylactic acid (the molecular weight of the mPEG section is 750g/mol, the molecular weight of the PLA section is 2000-4000g/mol), fully dissolving, then carrying out negative pressure rotary evaporation, and heating the temperature by using a rotary evaporator to be not more than 50 ℃. Stopping rotary evaporation when the concentration is to 1/3 of the original volume, and filtering by using an ultrafiltration membrane with the pore diameter of 50 nm. Concentrating the ultrafiltration permeate to obtain 133 g of extract-like centella asiatica extract.
(4) And (3) mixing the asiatic pennywort herb extract obtained in the step (3) with 1300 ml of 95% ethanol, stirring for 20 minutes, filtering by using a 0.5-micron polypropylene membrane, discarding the filtrate, and collecting 48 g of a solid containing the asiatic pennywort herb extract.
(5) Putting the solid obtained in the step (4) into an ultrasonic reaction container, adding 140 g of 2-butanol, fully mixing, treating for 15 minutes by using a 0.22 mu m polypropylene membrane, and collecting filtrate, wherein the ultrasonic frequency is 20KHz, the power strength is 300W/square meter; adding 100 g of 2-butanol again, and repeating the steps; the two filtrates are combined, the 2-butanol solvent is removed by evaporation and dried to obtain 0.69 g of off-white madecassoside.
Example 2, high purity madecassoside was extracted.
(1) Weighing 120 g of centella asiatica whole plant, grinding and crushing the centella asiatica whole plant, and sieving the ground centella asiatica whole plant with a 12-mesh sieve. 100 g of the sieved centella powder is weighed and placed in a 2L round-bottom flask, 1 kg of ethyl acetate is added, the mixture is soaked for 1 hour at the temperature of 45 ℃, and the ethyl acetate is removed by filtration.
(2) The centella asiatica powder treated by the ethyl acetate is fully mixed with 1500 ml of aqueous solution containing hydrogen peroxide and 2-hydroxypropyl-beta-cyclodextrin. The weight percentage of the hydrogen peroxide in the aqueous solution is 15 percent, and the weight percentage of the 2-hydroxypropyl-beta-cyclodextrin is 5 percent. Heating in water bath at a temperature not higher than 80 deg.C, stirring at 120 rpm, and extracting for 1 hr; filtering to obtain extractive solution, adding 1500 ml of aqueous solution containing hydrogen peroxide and 2-hydroxypropyl-beta-cyclodextrin into the residue, extracting again in the above steps, and filtering to obtain extractive solution. Mixing the two extractive solutions, adding 60 g of 2-hydroxypropyl-beta-cyclodextrin, stirring at 50 deg.C for 3 hr, and stirring at 80 rpm to obtain herba Centellae extractive solution.
(3) And (3) sequentially filtering the centella asiatica extract obtained in the step (2) by using 0.5 mu m and 0.22 mu m polypropylene membranes. Then 30 g of methoxy-polyethylene glycol-polylactic acid (the molecular weight of the mPEG section is 750g/mol, the molecular weight of the PLA section is 2000-4000g/mol) is added, after full dissolution, negative pressure rotary evaporation is carried out, and the heating temperature of a rotary evaporator is not more than 50 ℃. Stopping rotary evaporation when the concentration is to 1/4 of the original volume, and filtering by using an ultrafiltration membrane with the pore diameter of 50 nm. The ultrafiltration permeate was concentrated to give 321 g of extract of centella asiatica.
(4) And (3) mixing the asiatic pennywort herb extract obtained in the step (3) with 2500 ml of 95% ethanol, stirring for 20 minutes, filtering by using a 0.5-micron polypropylene membrane, and discarding the filtrate to obtain 161 g of the asiatic pennywort herb extract-containing solid.
(5) Mixing the solid obtained in the step (4) with 405 g of 2-butanol, placing the mixture in an ultrasonic reactor, carrying out ultrasonic treatment for 25 minutes by adopting 10KHz and power intensity of 200W/square meter, filtering the mixture by using a 0.22 mu m polypropylene membrane, and collecting filtrate; mixing the solid with 400 g of 2-butanol, carrying out ultrasonic treatment for 15 minutes, filtering by using a 0.22 mu m polypropylene membrane, and collecting filtrate; mixing the two filtrates, evaporating to remove the 2-butanol solvent under negative pressure, and drying to obtain 0.70 g of white madecassoside.
Comparative example 1
This comparative example provides a method for extracting madecassoside, which differs from example 1 in that: the solution for extracting the centella asiatica powder does not contain hydrogen peroxide and is decolorized by using activated carbon. The method comprises the following specific steps.
(1) Taking the whole herb of centella asiatica, pulverizing, and sieving with a 10-mesh sieve. Removing powder with too large particle size and unable to pass through sieve mesh, weighing 100 g of sieved herba Centellae powder, placing in 2L round bottom flask, adding 1 kg of ethyl acetate, soaking at 40 deg.C for 1.5 hr, and filtering to remove ethyl acetate.
(2) The cyclodextrin used in this comparative example was 2-hydroxypropyl- β -cyclodextrin, molecular weight 1541.54; the molecular formula is C42H63O35(C3H7O)7. Accurately weighing cyclodextrin and dissolving the cyclodextrin in deionized water to obtain an aqueous solution with 2 percent of cyclodextrin by weight. And (2) fully mixing the centella asiatica powder treated by the ethyl acetate in the step (1) with 1000 ml of aqueous solution of cyclodextrin. Heating in water bath at a temperature not higher than 75 deg.C, stirring at 120 rpm, and extracting for 1 hr; the extract is filtered off, the residue is again extracted with 1000 ml of an aqueous solution of cyclodextrin by the above procedure and the extract is again filtered off. Mixing the two extractive solutions, adding 20 g of cyclodextrin into the solution, stirring at 50 deg.C for 3 hr at a stirring speed of 80 rpm to obtain herba Centellae extractive solution.
(3) Filtering the centella asiatica extract obtained in the step (2) by using 0.5 mu m and 0.22 mu m polypropylene membranes in sequence, then adding 20 g of methoxy-polyethylene glycol-polylactic acid (the molecular weight of the mPEG section is 750g/mol, the molecular weight of the PLA section is 2000-4000g/mol), fully dissolving, then carrying out negative pressure rotary evaporation, and heating the temperature by using a rotary evaporator to be not more than 50 ℃. Stopping rotary evaporation when the concentration is to 1/3 of the original volume, and filtering by using an ultrafiltration membrane with the pore diameter of 50 nm. Concentrating the ultrafiltration permeate to obtain 142 g of extract-like centella asiatica extract.
(4) And (4) mixing the asiatic pennywort herb extract obtained in the step (3) with 1200 ml of 95% ethanol, stirring for 20 minutes, filtering by using a 0.5-micron polypropylene membrane, and discarding the filtrate to obtain 48 g of a solid containing the asiatic pennywort herb extract.
(5) Putting the solid obtained in the step (4) into an ultrasonic reaction container, adding 120 g of 2-butanol, fully mixing, treating for 15 minutes by using a 0.22 mu m polypropylene membrane, and collecting filtrate, wherein the ultrasonic frequency is 20KHz, the power strength is 300W/square meter; adding 120 g of 2-butanol again, and repeating the steps; the two filtrates were combined, 0.24 g (0.1% of the total weight of the two filtrates) of activated carbon was added to the filtrate, and after decolorizing with stirring at 50 ℃ for 15 minutes, the activated carbon was removed by filtration. Collecting filtrate, evaporating to remove 2-butanol solvent, and drying to obtain 0.42 g of quasi-white madecassoside.
Comparative example 2
Comparative example 2 provides a method for extracting madecassoside, compared with example 1, the difference is that the solution for extracting the centella asiatica powder in the step (2) is 2% of 2-hydroxypropyl-beta-cyclodextrin aqueous solution, and hydrogen peroxide is not contained; and methoxy-polyethylene glycol-polylactic acid is not added in the step (3). The method comprises the following specific steps.
(1) Taking the whole herb of centella asiatica, pulverizing, and sieving with a 10-mesh sieve. Removing powder with too large particle size and unable to pass through sieve mesh, weighing 100 g of sieved herba Centellae powder, placing in 2L round bottom flask, adding 1 kg of ethyl acetate, soaking at 40 deg.C for 1.5 hr, and filtering to remove ethyl acetate.
(2) The cyclodextrin used in this comparative example was 2-hydroxypropyl- β -cyclodextrin, molecular weight 1541.54; the molecular formula is C42H63O35(C3H7O)7. Accurately weighing cyclodextrin and dissolving the cyclodextrin in deionized water to obtain an aqueous solution with 2 percent of cyclodextrin by weight. And (2) fully mixing the centella asiatica powder treated by the ethyl acetate in the step (1) with 1000 ml of aqueous solution of cyclodextrin. Water (W)Heating in bath at a temperature not higher than 75 deg.C, stirring at 120 rpm, and extracting for 1 hr; the extract is filtered off, the residue is again extracted with 1000 ml of an aqueous solution of cyclodextrin using the procedure described above, and the extract is again filtered off. Mixing the two extractive solutions, adding 20 g of cyclodextrin into the solution, stirring at 50 deg.C for 3 hr at a stirring speed of 80 rpm to obtain herba Centellae extractive solution.
(3) Filtering the centella asiatica extract obtained in the step (2) by using 0.5 mu m and 0.22 mu m polypropylene membranes in sequence, collecting filtrate, and distilling under negative pressure, wherein the distillation heating temperature is not more than 50 ℃. The distillation was stopped when the concentration reached 1/3 in the original volume and filtration was carried out using an ultrafiltration membrane with a pore size of 50 nm. The ultrafiltration permeate was concentrated to obtain 149 g of extract of centella asiatica.
(4) And (3) mixing the asiatic pennywort herb extract obtained in the step (3) with 1200 ml of 95% ethanol, stirring for 20 minutes, filtering by using a 0.5-micron polypropylene membrane, and discarding the filtrate to obtain 49 g of a solid containing the asiatic pennywort herb extract.
(5) Putting the solid obtained in the step (4) into an ultrasonic reaction container, adding 145 g of 2-butanol, fully mixing, treating for 15 minutes by using a 0.22 mu m polypropylene membrane, and collecting filtrate, wherein the ultrasonic frequency is 20KHz, the power intensity is 300W/square meter; adding 100 g of 2-butanol again, and repeating the steps; the two filtrates are combined, the 2-butanol solvent is removed by evaporation and dried to obtain light yellow brown madecassoside 0.73 g.
Comparative example 3
Comparative example 3 provides a method for extracting madecassoside, which is different from example 2 only in that no methoxy-polyethylene glycol-polylactic acid is added in step (3). The method comprises the following specific steps.
(1) Weighing 120 g of centella asiatica whole plant, grinding and crushing the centella asiatica whole plant, and sieving the ground centella asiatica whole plant with a 12-mesh sieve. 100 g of the sieved centella powder is weighed and placed in a 2L round-bottom flask, 1 kg of ethyl acetate is added, the mixture is soaked for 1 hour at the temperature of 45 ℃, and the ethyl acetate is removed by filtration.
(2) The centella asiatica powder treated by the ethyl acetate is fully mixed with 1500 ml of aqueous solution containing hydrogen peroxide and 2-hydroxypropyl-beta-cyclodextrin. The weight percentage of the hydrogen peroxide in the aqueous solution is 15 percent, and the weight percentage of the 2-hydroxypropyl-beta-cyclodextrin is 5 percent. Heating in water bath at a temperature not higher than 80 deg.C, stirring at 120 rpm, and extracting for 1 hr; the extract is filtered off, the residue is extracted again with the above-mentioned steps and the extract is filtered off. Mixing the two extractive solutions, adding 60 g of 2-hydroxypropyl-beta-cyclodextrin, stirring at 50 deg.C for 3 hr, and stirring at 80 rpm to obtain herba Centellae extractive solution.
(3) And (3) sequentially filtering the centella asiatica extract obtained in the step (2) by using 0.5 mu m and 0.22 mu m polypropylene membranes. Collecting filtrate, and distilling under negative pressure at a distillation heating temperature of 50 deg.C or below. The distillation was stopped when the concentration reached 1/4 in the original volume and filtration was carried out using an ultrafiltration membrane with a pore size of 50 nm. Concentrating the ultrafiltration permeate to obtain 331 g of extract-like centella asiatica extract.
(4) And (3) mixing the asiatic pennywort herb extract obtained in the step (3) with 3200 ml of 95% ethanol, stirring for 20 minutes, filtering by using a 0.5-micron polypropylene membrane, and discarding the filtrate to obtain 168 g of the solid containing the asiatic pennywort herb extract.
(5) Mixing the solid obtained in the step (4) with 420 g of 2-butanol, placing the mixture in an ultrasonic reactor, carrying out ultrasonic treatment for 25 minutes by adopting 10KHz and power intensity of 200W/square meter, filtering the mixture by using a 0.22 mu m polypropylene membrane, and collecting filtrate; mixing the solid with 420 g of 2-butanol, carrying out ultrasonic treatment for 15 minutes, filtering by using a 0.22 mu m polypropylene membrane, and collecting filtrate; the two filtrates are combined, the solvent is removed by evaporation and dried to obtain 0.72 g of white madecassoside.
Experimental example 1, purity analysis.
The purity of the madecassoside product obtained in each of the above examples and comparative examples was determined by HPLC analysis. The chromatographic conditions of HPLC analysis are the same as the content determination method under the item of centella asiatica in the section of 2020 edition of Chinese pharmacopoeia (page 296), and the analysis results are shown in Table 1.
TABLE 1 results of analysis of examples 1 and 2 and comparative examples 1, 2 and 3
According to the results of the above examples and comparative examples, it can be seen that the madecassoside sample prepared by the technical solution of the present invention has about 90% madecassoside content, low asiaticoside and asiaticoside B content, and contains no asiatic acid and madecassic acid. The technical scheme of the invention has obvious progress.
Experimental example 2, biosafety test.
The extracts obtained in example 1, example 2, comparative example 2 and comparative example 3 were subjected to biosafety testing according to the experimental procedures described in the inspection and quarantine industry standard SN/T2329-2009 cosmetic eye irritation/corrosiveness chick embryo chorioallantoic membrane test of the people's republic of China. Saline at a concentration of 0.9% was used as a blank control. Dissolving the extracts obtained in examples 1 and 2 in deionized water to prepare 5% and 30% aqueous solutions respectively; the extracts obtained in comparative examples 2 and 3 were dissolved in deionized water to prepare aqueous solutions having concentrations of 5% and 30%, respectively.
The formula for calculating the stimulation score method (IS for short) IS shown in the following formula I.
IS <1 means no irritation, IS <1 > or less IS <5 means mild irritation, IS <5 > or less IS <9 means moderate irritation, and IS > 9 means intense irritation. The results of the tests and calculations are given in table 2 below.
TABLE 2 results of biosafety experiments
| Sample (I) | Concentration of | When bleedingTime t (H) | Vascular melting t (L) | Blood coagulation t (C) | Total score | Irritation classification |
| Physiological saline | 0.9％ | 301 | 301 | 301 | 0.0 | Has no irritation |
| Example 1 | 5％ | 301 | 301 | 301 | 0.0 | Has no irritation |
| Example 2 | 30％ | 290 | 276 | 301 | 0.76 | Has no irritation |
| Comparative example 2 | 5％ | 287 | 245 | 298 | 1.63 | Slight stimulation |
| Comparative example 3 | 30％ | 60 | 106 | 301 | 8.56 | Moderate stimulation |
Biological safety tests show that the extract obtained in the example has lower biological irritation and better safety.
The above examples are only intended to illustrate the technical solution of the present invention, but not to limit it; although the present invention has been described in detail with reference to the foregoing embodiments, it will be understood by those of ordinary skill in the art that: the technical solutions described in the foregoing embodiments may still be modified, or some technical features may be equivalently replaced; and such modifications or substitutions do not depart from the spirit and scope of the corresponding technical solutions of the embodiments of the present invention.
Claims (8)
1. A method for extracting a centella asiatica extract is characterized by comprising the following steps:
(1) pulverizing and sieving the whole centella asiatica, soaking the centella asiatica in an organic solvent to remove fat-soluble substances, and then removing the solvent to collect the centella asiatica powder;
(2) stirring and extracting the centella powder obtained in the step (1) for multiple times by using an aqueous solution containing hydrogen peroxide and cyclodextrin, combining extracting solutions obtained for multiple times, adding the cyclodextrin, and fully stirring to obtain a centella extracting solution;
(3) sequentially filtering the centella asiatica extract in the step (2) by using 0.5-micrometer and 0.22-micrometer polypropylene membranes, adding methoxy-polyethylene glycol-polylactic acid, performing negative pressure rotary evaporation, concentrating to 1/3-1/4 of the original volume, using a 50nm ultrafiltration membrane, collecting ultrafiltration permeate, and concentrating to obtain an extract to obtain a centella asiatica extract;
(4) mixing the centella asiatica extract obtained in the step (3) with high-concentration ethanol, stirring, filtering by using a 0.5-micrometer polypropylene membrane, discarding the filtrate, and collecting the solid;
(5) mixing the solid collected in the step (4) with a low-boiling-point organic solvent, carrying out high-frequency high-power ultrasonic treatment, filtering by using a 0.22-micrometer polypropylene membrane, and collecting filtrate; repeating the above steps; mixing the filtrates, removing organic solvent by rotary evaporation, drying to obtain herba Centellae extract,
in the aqueous solution containing hydrogen peroxide and cyclodextrin in the step (2), the concentration of the hydrogen peroxide is 10-15%; the cyclodextrin is 2-hydroxypropyl-beta-cyclodextrin, the molecular weight is 1542, and the concentration is 2-5%.
2. The method for extracting centella asiatica extract according to claim 1, wherein the extraction method comprises: the weight ratio of the centella powder in the step (2) to the aqueous solution containing hydrogen peroxide and cyclodextrin is 1: 10-1: 15; the extraction temperature is 75-80 deg.C, and the extraction time is 2 times, each time for 1 hr.
3. The method for extracting centella asiatica extract according to claim 1, wherein the extraction method comprises: the addition amount of the cyclodextrin in the step (2) is 1-2% of the total weight of the aqueous solution containing hydrogen peroxide and cyclodextrin.
4. The method for extracting centella asiatica extract according to claim 1, wherein the extraction method comprises: the molecular weight of the mPEG section of the methoxy-polyethylene glycol-polylactic acid in the step (3) is 750g/mol, the molecular weight of the PLA section is 2000-4000g/mol, and the adding weight is 20-30% of the weight of the centella asiatica powder in the step (1).
5. The method for extracting centella asiatica extract according to claim 1, wherein the extraction method comprises: the weight ratio of the centella asiatica extract in the step (4) to the high-concentration ethanol is 1: 8.
6. The method for extracting centella asiatica extract according to claim 1, wherein the extraction method comprises: the weight ratio of the low-boiling point solvent to the solid in the step (5) is 5: 1; the frequency of the high-frequency high-power ultrasonic wave is 20KHz, and the power intensity is 300W/square meter.
7. The method for extracting centella asiatica extract according to claim 1, wherein the extraction method comprises: the low boiling point solvent of the step (5) is 2-butanol.
8. An extraction method of centella asiatica extract, characterized in that the extract obtained by the preparation method of claims 1-7 contains more than 89% of madecassoside, and the total content of asiaticoside and asiaticoside B is less than 6%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110193793.3A CN112957379B (en) | 2021-02-20 | 2021-02-20 | Method for extracting centella asiatica extract |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110193793.3A CN112957379B (en) | 2021-02-20 | 2021-02-20 | Method for extracting centella asiatica extract |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112957379A CN112957379A (en) | 2021-06-15 |
| CN112957379B true CN112957379B (en) | 2022-04-08 |
Family
ID=76285292
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110193793.3A Active CN112957379B (en) | 2021-02-20 | 2021-02-20 | Method for extracting centella asiatica extract |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112957379B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115043896A (en) * | 2022-06-22 | 2022-09-13 | 杭州瑞博天琛生物科技有限公司 | Extraction method and activity research of asiatic pennywort herb protein extract |
| CN115364014A (en) * | 2022-09-02 | 2022-11-22 | 广州弗恩生物科技有限公司 | Multi-effect moisturizing factor and preparation method thereof |
| CN116763700A (en) * | 2023-08-15 | 2023-09-19 | 广州蒂普生物科技有限公司 | Relief repair extract composition and application thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060106206A1 (en) * | 2002-12-10 | 2006-05-18 | Bayer Consumer Care Ag | Method for preparing a centella asiatica extract rich in madecassoside and in terminoloside |
| CN101323637A (en) * | 2008-07-29 | 2008-12-17 | 卢照凯 | Asiaticoside and preparation thereof |
| CN102477063A (en) * | 2010-11-24 | 2012-05-30 | 上海医药工业研究院 | Method for preparing high-purity madecassoside and asiaticoside B |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106380504B (en) * | 2016-08-25 | 2018-01-26 | 桂林益天成生物科技有限公司 | The method that madecassoside is extracted from centella |
-
2021
- 2021-02-20 CN CN202110193793.3A patent/CN112957379B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060106206A1 (en) * | 2002-12-10 | 2006-05-18 | Bayer Consumer Care Ag | Method for preparing a centella asiatica extract rich in madecassoside and in terminoloside |
| CN101323637A (en) * | 2008-07-29 | 2008-12-17 | 卢照凯 | Asiaticoside and preparation thereof |
| CN102477063A (en) * | 2010-11-24 | 2012-05-30 | 上海医药工业研究院 | Method for preparing high-purity madecassoside and asiaticoside B |
Non-Patent Citations (2)
| Title |
|---|
| β-环糊精流动相添加剂法分离测定积雪草总苷元中的羟基积雪草酸;潘见等;《色谱》;20070531(第3期);第316-319页 * |
| 环糊精水提法提取积雪草中的三萜类化合物;常春等;《西北药学杂志》;20180731;第33卷(第4期);第435页左栏倒数第1-3段 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN112957379A (en) | 2021-06-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112957379B (en) | Method for extracting centella asiatica extract | |
| CN106309251B (en) | A kind of Gotu Kola P.E and its application with anti-inflammatory Shu Min effect | |
| CN104840501B (en) | A kind of preparation method of chrysanthemum total flavone | |
| CN105254775B (en) | Aloe polysaccharide extraction method and aloe Sin-care composition | |
| CN101301319A (en) | Preparation of granada flower polyphenol and uses thereof | |
| CN1879656B (en) | Solid water soluble propolis composition and preparation method thereof | |
| EP1837029B2 (en) | Composition for prevention and treatment of coughs and colds | |
| CN101401843A (en) | Extracting method for active principle of traditional Chinese medicine red sage root | |
| CN114146037B (en) | Preparation method of purslane extracting solution | |
| CN107595996A (en) | A kind of preparation of the water-soluble antibacterial cream of wormwood compound Chinese medicine | |
| WO2021082889A1 (en) | Environmentally-friendly method of preparing composition containing anti-inflammatory active ingredient and application thereof | |
| JP4385359B2 (en) | Powder bath preparations having active ingredients from natural medicinal plants and their pretreated products | |
| CN100488543C (en) | Local externally applied itch stopping garlic liniments | |
| CN113081917A (en) | Female care solution containing hemp leaf extract and preparation method thereof | |
| CN114288705B (en) | Method for removing ginkgolic acid from ginkgo leaf extract | |
| CN110559237A (en) | preparation method of modified acanthopanax trifoliatus extract and application of modified acanthopanax trifoliatus extract in cosmetics | |
| CN107510836A (en) | A kind of bitter gourd polypeptide pharmaceutical composition for treating diabetic ulcer and preparation method thereof | |
| RU2351166C1 (en) | Production method for inuline of milk-witch gowan | |
| CN107626220B (en) | Method for promoting dissolution of flavone or glycoside compounds and application thereof | |
| CN103479704A (en) | Method for extracting total flavones from chrysanthemum | |
| CN109568200A (en) | A kind of method of ethyl alcohol-ammonium sulfate double-aqueous phase system separation and concentration asiaticoside | |
| CN112741117B (en) | Preparation method of herbal antibacterial disinfectant | |
| CN103083376B (en) | Can be used for the Rhizoma Ligustici extract for the treatment of rhinitis | |
| CN109985075B (en) | Ginkgo leaf extract injection and preparation method thereof | |
| CN101757037A (en) | Method for extracting propolis active ingredients by using semi-bionics technique |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CP01 | Change in the name or title of a patent holder | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 201500 Jinshan District, Shanghai Patentee after: Shanghai Jiakai Biological Co.,Ltd. Address before: 201500 Jinshan District, Shanghai Patentee before: SHANGHAI JIAKAI BIOLOGICAL TECHNOLOGY Co.,Ltd. |
|
| CP02 | Change in the address of a patent holder | ||
| CP02 | Change in the address of a patent holder |
Address after: No. 818 Tiangong Road, Jinshan District, Shanghai, 200540 Patentee after: Shanghai Jiakai Biological Co.,Ltd. Address before: 201500 Jinshan District, Shanghai Patentee before: Shanghai Jiakai Biological Co.,Ltd. |